公开(公告)号：US20240226262A9

公开(公告)日：2024-07-11

申请号：US18467682

申请日：2023-09-14

申请人： Prime Bio, Inc.

发明人： Bal Ram Singh

IPC分类号： A61K39/02 ,  A61K39/00 ,  A61K39/08 ,  A61K39/395 ,  A61P31/04 ,  C07K14/19 ,  C07K14/235 ,  C07K14/33 ,  C07K14/34 ,  C12N15/62 ,  C12N15/66 ,  C12N15/70

CPC分类号： A61K39/099 ,  A61K39/0018 ,  A61K39/08 ,  A61K39/39525 ,  A61P31/04 ,  C07K14/19 ,  C07K14/235 ,  C07K14/33 ,  C07K14/34 ,  C12N15/62 ,  C12N15/66 ,  C12N15/70 ,  A61K2039/542 ,  A61K2039/6031 ,  A61K2039/622

摘要： The present invention describes a second-generation tetanus toxoid vaccine and a process for the preparation thereof, comprising the steps of: inducing an E. Coli culture OD 600=0.5 by adding 0.2 mM IPTG; growing the culture at 14-16° C. for 14 to 20 hours; suspending the culture in 25 mM phosphate buffer containing 200 mM sodium chloride; adding 1% of triton-X-100 to the phosphate buffer, and adding the buffer to the culture; sonicating the culture for a period of 3 minutes (at 5 sec on/off pulse) at 4° C. on cold beads; centrifuging the culture for 60 to 90 minutes; collecting and purifying a supernatant using Ni-NTA affinity column with an eluant; and combining the supernatant into a pool with contaminated bands and concentrating using Centriprep-30 centrifuge filters (30 kDa pores).

公开(公告)号：US20230233662A1

公开(公告)日：2023-07-27

申请号：US18299676

申请日：2023-04-12

申请人： CureVac SE

发明人： Karl-Josef KALLEN ,  Thomas KRAMPS ,  Margit SCHNEE ,  Benjamin PETSCH ,  Lothar STITZ

IPC分类号： A61K39/155 ,  A61K39/12 ,  A61K39/145 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  A61P31/16 ,  A61K39/00 ,  A61K45/06

CPC分类号： A61K39/155 ,  A61K39/12 ,  A61K39/145 ,  A61K47/59 ,  A61K47/6455 ,  A61K47/6921 ,  A61P31/16 ,  A61K39/00 ,  A61K45/06 ,  A61K2039/53 ,  A61K2039/55 ,  A61K2039/572 ,  C12N2760/16134 ,  Y02A50/30 ,  A61K2039/54 ,  A61K2039/55583 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/622 ,  C12N2760/18534 ,  C12N2760/18571

摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

公开(公告)号：US11672856B2

公开(公告)日：2023-06-13

申请号：US16910845

申请日：2020-06-24

申请人： CureVac AG

发明人： Karl-Josef Kallen ,  Thomas Kramps ,  Margit Schnee ,  Benjamin Petsch ,  Lothar Stitz

IPC分类号： A61K39/145 ,  A61K39/155 ,  A61K39/12 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  A61P31/16 ,  A61K39/00 ,  A61K45/06

CPC分类号： A61K39/155 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K45/06 ,  A61K47/59 ,  A61K47/6455 ,  A61K47/6921 ,  A61P31/16 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55 ,  A61K2039/55583 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/622 ,  C12N2760/16134 ,  C12N2760/18534 ,  C12N2760/18571 ,  Y02A50/30

摘要： The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

公开(公告)号：US20180177726A1

公开(公告)日：2018-06-28

申请号：US15897025

申请日：2018-02-14

申请人： IMMUNOVACCINE TECHNOLOGIES, INC.

发明人： Pirouz M. DAFTARIAN ,  Marc MANSOUR ,  Bill POHAJDAK ,  Robert G. BROWN ,  Wijbe M. KAST

IPC分类号： A61K9/127 ,  C07K14/005 ,  A61K9/00 ,  A61K31/4745 ,  A61K39/00 ,  C12N9/90 ,  A61K39/12 ,  A61K39/385 ,  C07K14/47 ,  A61K47/64

CPC分类号： A61K9/127 ,  A01K2267/0331 ,  A61K9/0024 ,  A61K31/4745 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/385 ,  A61K47/646 ,  A61K2039/545 ,  A61K2039/55544 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/585 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/622 ,  A61K2039/627 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/4748 ,  C07K2319/00 ,  C12N9/90 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12Y503/03012

摘要： The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic T lymphocyte (CTL) response and methods for their use in the treatment of cancer.

公开(公告)号：US20180169208A1

公开(公告)日：2018-06-21

申请号：US15886112

申请日：2018-02-01

申请人： Wichita State University ,  Case Western Reserve University

发明人： James G. Bann ,  Masaru Miyagi

IPC分类号： A61K39/07 ,  A61K45/06 ,  A61K39/40 ,  A61K39/00

CPC分类号： A61K39/07 ,  A61K39/40 ,  A61K45/06 ,  A61K2039/6031 ,  A61K2039/622

摘要： Immunogenic compositions against Bacillus anthracis comprising a stabilized protective antigen complex are disclosed. The stabilized complex comprises protective antigen protein and capillary morphogenesis protein-2, with the capillary morphogenesis protein-2 being bound to the protective antigen protein along a binding interface. The stabilized protective antigen complex has increased thermal and structural stability, along with resistance to premature proteolytic degradation. Methods of using the same to induce an immunogenic response in a subject against B. anthracis infection are also disclosed.

公开(公告)号：US20180008688A1

公开(公告)日：2018-01-11

申请号：US15641427

申请日：2017-07-05

申请人： Augusta University Research Institute, Inc.

发明人： David H. Munn

IPC分类号： A61K39/00 ,  C07K14/47 ,  A61K39/385

CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K39/385 ,  A61K39/39 ,  A61K2039/5158 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/572 ,  A61K2039/622 ,  C07K14/4748

摘要： Provided are methods and compositions for enhancing treatment of a cancer by administering a therapeutic agent for the treatment of a cancer together with a second agent that elevates the level of protein p53. The second agent generates in the tumor a population of dendritic cells expressing at least one of Batf3, IRF5, CD103, and XCR1. The second therapeutic agent can also suppress an autoimmune response to non-cancerous tissue in the patient if generated by an immunotherapeutic agent. The method can further comprise administering a PTEN phosphatase inhibitor.

公开(公告)号：US20170320942A1

公开(公告)日：2017-11-09

申请号：US15607661

申请日：2017-05-29

申请人： S-TARGET THERAPEUTICS GMBH

发明人： Geert Mudde ,  Gottfried Himmler

IPC分类号： C07K16/28 ,  C07K14/435 ,  A61K39/00

CPC分类号： C07K16/283 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/35 ,  A61K2039/55561 ,  A61K2039/57 ,  A61K2039/6056 ,  A61K2039/622 ,  C07K14/43531 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/64 ,  C07K2317/66 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/74

摘要： A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.

公开(公告)号：US20170258889A1

公开(公告)日：2017-09-14

申请号：US15492363

申请日：2017-04-20

申请人： Trustees of Tufts College

发明人： David L. Kaplan ,  Fiorenzo G. Omenetto

IPC分类号： A61K39/20 ,  A61K39/00 ,  A61K39/02 ,  A61K39/04 ,  A61K39/08 ,  A61K39/09 ,  A61K39/095 ,  A61K39/12 ,  A61K39/165 ,  A61K47/42 ,  A61K47/46 ,  A61K9/00 ,  A61K9/06 ,  A61K9/14 ,  A61K9/19 ,  A61K9/50 ,  A61K9/70 ,  B82Y5/00 ,  A61K38/00

CPC分类号： A61K39/20 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/146 ,  A61K9/19 ,  A61K9/5026 ,  A61K9/5063 ,  A61K9/7007 ,  A61K38/00 ,  A61K39/0015 ,  A61K39/02 ,  A61K39/04 ,  A61K39/08 ,  A61K39/092 ,  A61K39/095 ,  A61K39/099 ,  A61K39/12 ,  A61K39/165 ,  A61K47/42 ,  A61K47/46 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/6031 ,  A61K2039/622 ,  A61K2039/64 ,  A61K2039/70 ,  B82Y5/00 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2770/36234 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/466 ,  Y02A50/484

摘要： Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.

公开(公告)号：US20170128593A1

公开(公告)日：2017-05-11

申请号：US15206329

申请日：2016-07-11

申请人： NATIONAL CHENG KUNG UNIVERSITY

发明人： Yee-Shin LIN ,  Yu-Hung CHEN

IPC分类号： A61K39/193 ,  A61K39/12 ,  C12N7/00

CPC分类号： A61K47/6939 ,  A61K39/12 ,  A61K39/39 ,  A61K47/6921 ,  A61K47/6933 ,  A61K47/6935 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/55583 ,  A61K2039/6031 ,  A61K2039/6093 ,  A61K2039/622 ,  A61K2039/64 ,  C12N7/00 ,  C12N2770/24134 ,  Y02A50/386

摘要： The present invention relates to an immunostimulatory nanocomplex. The immunostimulatory nanocomplex comprises polyglutamic acid (PGA), a first positively charged substance, a second positively charged substance and a dengue viral protein for holding the dengue viral protein inside. The immunostimulatory nanocomplex is characterized by having a nonuniformally and positively charge distribution along a radial direction thereof. The nonuniformally and positively charge distribution comprises a first electrically charged portion having substantially electrical neutrality, a second electrically charged portion surrounding the first electrically charged portion, and a third electrically charged portion surrounding the second electrically charged portion. The third electrically charged portion has a third volume charge density more than a second volume charge density of the second electrically charged portion, thereby enhancing CD8(+) T-cell response and higher antibody titer after administrating an organism with the immunostimulatory nanocomplex.

公开(公告)号：US20150328296A1

公开(公告)日：2015-11-19

申请号：US14411233

申请日：2013-06-26

申请人： UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO

发明人： Jaime MAS OLIVA ,  Blanca Alicia DELGADO COELLO ,  Victor Guadalupe GARCIA GONZALEZ ,  Armando PEREZ TORRES

IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K35/74 ,  A61K47/48

CPC分类号： A61K39/0005 ,  A61K9/0043 ,  A61K9/1075 ,  A61K35/74 ,  A61K38/08 ,  A61K39/39 ,  A61K47/6909 ,  A61K2039/543 ,  A61K2039/55555 ,  A61K2039/622 ,  A61K2300/00

摘要： The present invention provides a novel vaccine compound of micellar nanoparticles to be administered intranasally to treat and/or prevent the disease called atherosclerosis, which results from an abnormal metabolism of circulating lipids. The novelty of the vaccine compound of the present invention is the use of Archaebacterian lipids, lysophosphatidylcholine, and phosphatidylcholine, which give nanoparticles stability and facilitates antigen presentation in its appropriate secondary peptidic conformation. A novel process for the preparation of vaccine compounds which allows obtaining homogeneous nanoparticles with high stability is also presented in this invention.

摘要翻译： 本发明提供了鼻内给药的胶束纳米颗粒的新型疫苗化合物，用于治疗和/或预防由循环脂质的异常代谢引起的称为动脉粥样硬化的疾病。 本发明的疫苗化合物的新颖性是使用古细菌脂质，溶血磷脂酰胆碱和磷脂酰胆碱，其赋予纳米颗粒稳定性并促进其适当的次级肽构象中的抗原呈递。 本发明还提出了一种制备能够获得具有高稳定性的均相纳米颗粒的疫苗化合物的新方法。